PF-3644022
目录号 : GC14645
PF-3644022 是一种有效的、选择性的、具有口服活性和 ATP 竞争性的 MAPKAPK2 (MK2) 抑制剂，IC50 为 5.2 nM，Ki 为 3 nM。
Cas No.:1276121-88-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PF-3644022 is a potent and selective mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) inhibitor (Ki =3 nM). [1]
PF-3644022 is the first oral MK2 inhibitor in both acute and chronic models of inflammation. PF-3644022 reversibly ATP-competitive inhibits MK2 enzyme activity with good selectivity across 200 human kinases. [1]
In the human U937 monocytic cell line or peripheral blood mononuclear cells, PF-3644022 potently inhibits TNF production with IC50 value of 160 nM. In LPS-stimulated human whole blood, PF-3644022 blocks TNF and IL-6 production with IC50 values of 1.6 and 10.3 μM, respectively. In U937 cells and blood, Inhibition of TNF correlates closely with inhibition of phospho-heat shock protein 27, a target biomarker of MK2 activity. [1]
In the rat LPS-induced TNF model, PF-3644022 efficacy in the chronic inflammation model is strongly correlated with maintaining a Cmin higher than the EC50 measured. PF-3644022 exhibits efficaciously oral activity and good pharmacokinetic parameters in both the chronic streptococcal cell wall-induced arthritis model and the rat acute LPS-induced TNF model. [1]
References:
1. Mourey RJ, Burnette BL, Brustkern SJ et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010 Jun;333(3):797-807. doi: 10.1124/jpet.110.166173. Epub 2010 Mar 17.
| Cas No. | 1276121-88-0 | SDF | |
| 化学名 | (R)-10-methyl-3-(6-methylpyridin-3-yl)-11,12-dihydro-10H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-ol | ||
| Canonical SMILES | CC1=NC=C(C2=NC(C=CC(S3)=C4C5=C3C(O)=N[C@](CN5)([H])C)=C4C=C2)C=C1 | ||
| 分子式 | C21H18N4OS | 分子量 | 374.46 |
| 溶解度 | <14.98mg/ml in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6705 mL | 13.3526 mL | 26.7051 mL |
| 5 mM | 0.5341 mL | 2.6705 mL | 5.341 mL |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6705 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet